Cardiovascular Disease Drug Development

Delivering Solutions Made Real® for cardiovascular disease.

Together, let’s tackle cardiovascular disease.

  • Obtain cardiovascular endpoints earlier using preclinical models

  • Successfully execute complex mega-trials with Xcellerate®, the world's largest clinical trials knowledgebase

  • Partner with a company that has conducted more than 350 global studies with over 200,000 patients during the past five years

Photo of a toy heart in a hand.
Your Needs

Revealing new opportunities in cardiovascular drug development.

Beating cardiovascular disease requires a strategic, scientific approach. From tracking changing disease patterns in an aging population to developing cutting edge approaches to disease management, it’s no easy task. That's why you need a trusted partner who keeps pace with the rapidly evolving marketplace and has vast experience with small molecules, device-based therapeutics and biologics. At Covance, our dedicated cardiovascular specialists have a unique combination of both academic and industry experience that provides you with insightful study design, predictive study management and operational service excellence. 

Enable success by leveraging our expertise and precision delivery.

The primary reason for late stage drug failure in cardiovascular trials is the inability to document improvement in outcomes. Therefore, we begin working with you as early as the preclinical phase to design outcomes oriented programs that help minimize risk and maximize your chance for success. 

  • Get answers on safety earlier using our nonclinical cardiovascular safety assessment techniques and gain critical information for your “go / no-go” decision

  • Add value to your study through our experience in cardiac ultrasound, magnetic resonance imaging, nuclear scanning and CT angiography by capitalizing on our team of physicians who currently serve, or have served, as academic and core imaging laboratory directors

  • Validate your drug’s safety and efficacy by proactively identifying those biomarkers – assays, multicomponent panels or imaging-based – that are most predictive of risk or success

  • Go beyond surrogate biomarkers by demonstrating actual improvements in cardiovascular outcomes with well-designed trials

  • Reach your clinical development goals faster with specialized design and conduct of Phase I - Phase IV trials across a wide range of small, molecule, devices and biologics including genetic therapies, peptides, enzyme replacement and stem cells

It is all about outcomes.

Navigating the specific complexities of cardiovascular mega-trials is a big challenge.  Success often depends on investigator interest and recruitment of appropriate patient populations.  To help point you toward success, we have partnered with cardiovascular academic research organizations (AROs) who provide both medical and scientific leadership as well as insight into investigator and site quality. This partnership, in combination with Covance’s proprietary Xcellerate® knowledgebase—the world’s largest database of site selection and clinical laboratory data—enables you to identify patients for your trial faster, saving valuable time and money.

Once your trial is up and running, we will help to further reduce your timelines through proven operational efficiencies learned from prior successes in more than 200 global clinical endpoint trials.

Our Integrated Services

End-to-end solutions aligned with your needs.

We deliver a holistic suite of services for cardiovascular drug development. From lead optimization through commercialization, we have the expertise and resources to help manage the complexity of your molecule and transform your results.